Clinical trials / NCT04617054
NCT04617054Phase 2Terminated

Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion

Study sponsor: Nuvation Bio Inc. · NUVB

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2024-12-06Actual
Enrollment · participants14Actual
Source updated2026-01-21Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 6 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Best overall response (BOR)

+ After

Measure: Objective response rate (ORR)

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

40 participants (planned)

+ After

14 participants (actual)

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

30 Apr 2024

+ After

6 Dec 2024

Recruitment status changed

− Before

Recruiting

+ After

Terminated

Check registry source